Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The American Journal of Clinical Nutrition, 120 (5), 1245-1258
Drugmakers are actively working to secure FDA approval for other clinical indications as well
One is the addition of prebiotics, at least in Akkermansia and Glucose Control
-the-right-way-seo-graphics-gs.png?sfvrsn=5784682_3)
The youngest patients, Gen Z, reported the highest rates (61%), followed by millennials (34%), Gen X (21%), and baby boomers (19%)
In 2025, the company reported a -1.73% YoY (Jan-Dec25) decline in revenue, reflecting portfolio dynamics: Entyvio ($6.14B) continues to anchor growth in inflammatory bowel disease, Takhzyro ($1.44B) shows steady momentum in rare diseases, while Gattex/Revestive ($913.56M) remains a solid contributor in gastrointestinal disorders partially offset by generic pressure and loss of exclusivity in some legacy products
Just spray, swish & swallow
US$ 20.31
US$ 26.29
US$ 22.25
US$ 25.46
US$ 22.95
US$ 23.73
US$ 20.20
US$ 25.43
US$ 27.13
